08:42 AM EDT, 08/09/2024 (MT Newswires) -- Avidity Biosciences ( RNA ) said Friday that AOC 1044, or delpacibart zotadirsen or del-zota, showed a 25% increase of normal in dystrophin production and a 37% increase in exon 44 skipping in a phase 1/2 trial in people living with Duchenne muscular dystrophy.

The company also said that del-zota reduced creatine kinase levels to near normal with greater than 80% reduction compared to baseline. It was also found to be safe and tolerable, with most of the adverse events observed to be mild or moderate, according to Avidity.

Shares of the company rose more than 21% in recent premarket trading.

Price: 50.73, Change: +8.86, Percent Change: +21.15